 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Specialist in Intensive Care, Intensive Care Unit, Hospital General Universitario de Elche, Elche, Spain
Specialist in Hospital Pharmacy, Pharmacy Service, Hospital General Universitario de Elche
Specialist in Hospital Pharmacy, Pharmacy Service, Hospital General Universitario de Elche
Resident in Hospital Pharmacy, Pharmacy Service, Hospital General Universitario de Elche
Specialist in Intensive Care, Intensive Care Unit, Hospital General Universitario de Elche
Reprints: Dr. Borrás-Blasco, Servicio de Farmacia, Hospital General Universitario de Elche, Camí de l'Almazara 11, Elche 03203 (Alicante) Spain, fax 34 966679162, jborrasb{at}sefh.es
OBJECTIVE: To report a probable interaction between meropenem and valproic acid that resulted in the development of epileptic seizures.
CASE SUMMARY: A 21-year-old woman presented to our emergency department because of a new-onset, generalized tonic–clonic seizure and was admitted to the intensive care unit. Treatment with valproic acid 1000 mg as a continuous intravenous infusion over 24 hours was initiated. On day 6, the serum concentration of valproic acid was 52.5 µg/mL. On day 13, treatment with intravenous meropenem 1 g 3 times daily was started. On day 15, when the patient was afebrile, numerous myoclonic episodes occurred involving her arms and face; the serum concentration of valproic acid at that time was 42 µg/mL. The valproic acid dose was increased to 2880 mg. Two days later, a generalized tonic–clonic seizure occurred despite the increased dosage, and the plasma concentration of valproic acid fell to 7 µg/mL. The valproic acid dose was increased the following day to 3600 mg; however, the serum concentrations remained <10 µg/mL. On day 19, based on the results of a blood culture and the suspicion of an interaction between meropenem and valproic acid, meropenem therapy was suspended. The serum concentration of valproic acid was 52.4 µg/mL on day 27. Three days later, the patient was asymptomatic and was discharged.
DISCUSSION: Coadministration of valproic acid and other drugs that are metabolized by the hepatic cytochrome P450 isoenzyme system can lead to clinically relevant interactions by induction or inhibition of enzymes in shared metabolic pathways. In view of studies in experimental models, the interaction between carbapenem antibiotics and valproic acid is at least possible. Use of the Naranjo probability scale indicated a probable relationship between acute seizures and a meropenem–valproic acid interaction in this patient.
CONCLUSIONS: This case report provides strong evidence for an interaction between valproic acid and meropenem. Clinicians should be aware of this potential interaction that may be associated with a serious adverse effect as the result of the decrease of the valproic acid serum concentrations.
Key Words: meropenem, seizures, valproic acid
Published Online, February 8, 2005. www.theannals.com, DOI 10.1345/aph.1E358
This article has been cited by other articles:
|
|
 |
|
  S. Haroutiunian, Y. Ratz, B. Rabinovich, M. Adam, and A. Hoffman Valproic Acid Plasma Concentration Decreases in a Dose-Independent Manner Following Administration of Meropenem: A Retrospective Study J. Clin. Pharmacol., November 1, 2009; 49(11): 1363 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Baughman The Use of Carbapenems in the Treatment of Serious Infections J Intensive Care Med, July 1, 2009; 24(4): 230 - 241. [Abstract] [PDF]
|
|
|
|
 |
|
 B. F. Shneker, P. D. Baylin, and M. E. Nakhla LINEZOLID INDUCING COMPLEX PARTIAL STATUS EPILEPTICUS IN A PATIENT WITH EPILEPSY Neurology, January 27, 2009; 72(4): 378 - 379. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Spriet, J. Goyens, W. Meersseman, A. Wilmer, L. Willems, and W. V. Paesschen Interaction Between Valproate and Meropenem: A Retrospective Study Ann. Pharmacother., July 1, 2007; 41(7): 1130 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Spriet, W. Meersseman, E. De Troy, A. Wilmer, M. Casteels, and L. Willems Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus Am. J. Health Syst. Pharm., January 1, 2007; 64(1): 54 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhou Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? J. Clin. Pharmacol., November 1, 2006; 46(11): 1268 - 1289. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
